Publisher: University of Calabar Teaching Hospital

An Open Label 14-Day Therapeutic Efficacy Trial of Artesunate Plus Amodiaquine For Treating Uncomplicated Falciparum Malaria In Calabar, Nigeria.

F. A. Odey, M. M. Meremikwu, A. Oyo-ita, C. M. Oringanje, E. A. Iwasam, A. A. Alaribe, B. Oduwole, V. Asiegbu, E. N. U. Ezedinachi
KEYWORDS: Artesunate, Amodiaquine, drug trail, treatment, uncomplicated malaria


Artesunate combined with amodiquine isone of the two artemisinin combined therapy (ACT) approved for treatment of uncomplicated malaria in Nigeria. It is also the first-line anti-malarial for the treatment of uncomplicated malaria in 18 African countries. The aim of this study was to assess the 14 days therapeutic efficacy of a co-packaged combination of artesunate andamodiaquine for treating uncomplicated plasmodium falciparum therapeutic efficacy trail.Children e"6 months and adults with uncomplicated plasmodiumfalciparum malaria were screened for enrolment. Patients with parasite density of 1,000-200,000 were enrolled into the study. All treatments were observed by a research nurse. Patients were seen on Days 1,2,3,7, and 14 for clinical assessment and laboratory tests. Data that was generated was double entered and analysed with EPI-Info version 6. Six hundred and five patients were screened and 99 consisting of 56 males and 43 females were enrolled. Fifly-two of those enrolled were under fives while 47 were 5 years and above. Ninety-two completed the study and evaluated by day14 (49<5 children and 43e"5). Therapeutic efficacy was 100% in the per protocol population. Twenty-fours after enrolment, parasitic density had dropped by over 99%. Commonest adverse event was cough. Both haematological and biochemical indices did not deviate significantly from baseline values at the end of the study. This 14-day in-vivo therapeutic efhcacy trail of the combination of artesunate plus amodiaquine showed high efficacy but%

View Online
Publication Year
Place Of Publication